axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • P42
SMICES
5 May 2019
SETES
5 May 2019

P42

P42

Development of P42 peptide, orphan drug for Huntington's disease

Available technology

Desired partnership(s)

  • Start-up

IP

  • Patent

Establishment(s)

  • University of Montpellier
  • Inserm
  • CNRS
  • EPHE

Laboratory(ies)

  • Mécanismes moléculaires dans les démences neurodégénératives (MMDN)
  • Labo 2

Keywords

  • Neurodegenerative diseases
  • Huntington

Co-financed by

Context

Huntington’s disease is a genetic and hereditary neurodegenerative disease that results mainly in a profound and severe alteration of a patient’s physical and intellectual abilities, such as abnormal movement and behavioral disorders. When the gene coding for the huntingtin protein (HTT) presents an abnormally large repetition of the CAG (cytosine-adenine-guanine) triplet, the mutated protein possesses an expansion of polyQ (poly-glutamine) in its N-terminal part. When this domain exceeds 35Q, the mutated polyQ-Htt (mHtt) forms accumulations and a deterioration of striatum neurons is observed

Benefits

Huntington’s is a rare orphan disease for which there is currently no effective treatment that is acceptable for patients. This project seeks to bring out an efficient new first-in-class drug to treat Huntington's disease: peptide P42. P42 has demonstrated its efficacy both in vitro and in vivo with animal models; it presents an original and unique action mechanism; and it has earned the status of “Orphan Drug.” One of the other benefits of this project is to be able to obtain a new efficacy biomarkers (for preclinical and clinical applications), which is a need that has also been identified clearly by doctors, particularly during clinical trial phases.

Applications

Primary: Huntington’s disease Secondary: other neurodegenerative diseases and depression (leveraging the neuro-protective activity of P42)

AVAILABLE TECHNOLOGY I Peptide – Huntington

Share
4

Related posts

8 September 2021

StabCFTR


En savoir +
6 July 2021

HTLV-1


En savoir +
23 June 2021

GEOSOTECH


En savoir +
© 2023, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French